Pluri Inc
PLUR
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.9M
Close$
$-2.91
379.7% downside
Current Fair Value
379.7% downsideOvervalued by 379.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.90 Million |
|---|---|
| Enterprise Value | $14.92 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.44 |
| Beta | 0.67 |
| Outstanding Shares | 10,824,311 |
Return
| Return on Equity | 108.77% |
|---|---|
| Return on Assets | -155.16% |
| Return on Invested Capital | 152.28% |
Valuation & Multiples
| P/E Ratio | -0.41 |
|---|---|
| PEG | 1.82 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14.68 |
| Enterprise Value to EBIT | -0.59 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | -0.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$655,000
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.26%▼ 0.00% |
|---|---|
| Total Invested | $55,311▼ 39.43% |
| Investors Holding | 16▲ 3.00% |
ESG Score
No data
About Pluri Inc
152 employees
CEO: Zalman Aberman Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell...